ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Microbial Collagenase

Also written as “EN3835”, “Santyl” and “AA4500”.

Its studies are mostly in Cellulite · Penile Induration · Dupuytren Contracture · Diabetic Foot · Bursitis, led by 5 companies.

Drug pageMicrobial Collagenase: every studyMany companies study it; this page follows only the 42 they lead. All 71 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 17, 201142 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keenova Therapeutics382 open or runningphase 4since Dec 17, 2011Sep 11, 2007Dec 2027phase 3 · NCT07759362
Advance Biofacturesits history only10 open or runningphase 1since Aug 22, 2016Aug 22, 2016none ahead
Asahi Kasei Therapeuticsits history only10 open or runningphase 3since Apr 27, 2012Apr 27, 2012none ahead
Luxurgeryits history only10 open or runningphase 4since Mar 24, 2022Mar 24, 2022none ahead
Manhattan Medical Research Practice, PLLCits history only10 open or runningphase 4since Nov 30, 2018Nov 30, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Sep 11, 2007.

  1. Jul 5, 2018Phase 2 study in CelluliteNCT03632993 · 64 enrolled · United States
  2. Sep 15, 2018Phase 1 study in CelluliteNCT03675685 · 12 enrolled · United States
  3. Nov 18, 2019Phase 3 study in CelluliteNCT04170296 · 153 enrolled · United States, Puerto Rico
  4. Dec 11, 2019Phase 2 study in CelluliteNCT04209530 · 7 enrolled · United States
  5. Jan 2, 2020Phase 2 study in Characteristics of Subcutaneous TissueNCT04236635 · 10 enrolled · United States
  6. Jul 29, 2020Phase 2 study in BursitisNCT04496167 · 198 enrolled · United States
  7. Oct 2, 2020Phase 2 study in CelluliteNCT04580303 · 35 enrolled · United States
  8. Nov 29, 2021Phase 2 study in Fibromatosis, PlantarNCT05152173 · 176 enrolled · United States
  9. Feb 15, 2022Phase 3 study in Fibromatosis, PlantarNCT05254457 · 145 enrolled · United States
  10. Jun 9, 2022Phase 2 study in CelluliteNCT05419505 · 91 enrolled · United States
  11. Nov 21, 2023Phase 3 study in Fibromatosis, PlantarNCT06151197 · 436 enrolled · United States, Puerto Rico
  12. Dec 5, 2023Phase 2 study in Fasciitis, PlantarNCT06169319 · 231 enrolled · United States
  13. Aug 7, 2026Phase 3 study in Flexible HammertoeNCT07759362 · 554 planned · United States
  14. Sep 23, 2026Phase 3 study in Flexible HammertoeNCT07846280 · 470 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Flexible HammertoeNCT07759362
  2. Dec 2028Primary completion: phase 3 study in Flexible HammertoeNCT07846280

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 38 Keenova Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07846280Flexible Hammertoe · United States3RecruitingDec 2028470
NCT07759362Flexible Hammertoe · United States3RecruitingDec 2027554
NCT06169319Fasciitis, Plantar · United States2CompletedSep 30, 2024231
NCT06151197Fibromatosis, Plantar · United States, Puerto Rico3CompletedJun 9, 2026436
NCT05419505Cellulite · United States2CompletedJan 3, 202391
NCT05254457Fibromatosis, Plantar · United States3CompletedMar 21, 2024145
NCT05152173Fibromatosis, Plantar · United States2CompletedJan 10, 2023176
NCT04580303Cellulite · United States2CompletedAug 30, 202135
NCT04496167Bursitis · United States2CompletedApr 14, 2022198
NCT04236635Characteristics of Subcutaneous Tissue · United States2CompletedSep 23, 202010
NCT04209530Cellulite · United States2TerminatedJul 23, 20207
NCT04170296Cellulite · United States, Puerto Rico3CompletedOct 6, 2020153
NCT03675685Cellulite · United States1CompletedNov 1, 201812
NCT03632993Cellulite · United States2CompletedJan 24, 201964
NCT03526549Cellulite · United States3CompletedOct 8, 2021483
NCT03446781Cellulite · United States3CompletedSep 26, 2018422
NCT03428750Cellulite · United States3CompletedSep 26, 2018423
NCT03329989Cellulite · United States2CompletedSep 5, 2018158
NCT02942160Cellulite · United States2CompletedJun 14, 2018259
NCT02724644Cellulite · United States2CompletedSep 2016375
NCT02193828Dupuytren Contracture · United States, Australia2CompletedDec 201476
NCT02006719Bursitis · United States, Australia2CompletedDec 2014322
NCT01987986Cellulite · United States2CompletedAug 2014150
NCT01685437Penile Induration3CompletedDec 2013189
NCT01518907Cellulite · United States1CompletedDec 201299
NCT01498640Dupuytren Contracture · United States, Australia, Sweden and more4CompletedOct 201352
NCT01483963Bursitis · United States2CompletedFeb 201350
NCT01430169Penile Induration · United States2CompletedNov 201120
NCT01407068Dupuytren Contracture · United States, Australia3CompletedFeb 201260
NCT01243411Penile Induration · United States, Denmark, France and more3CompletedAug 2012348
NCT01221623Penile Induration · United States, Australia3CompletedMar 2012418
NCT01221597Penile Induration · United States, Australia3CompletedApr 2012418
NCT00755222Penile Induration · United States2CompletedDec 2009147
NCT00533273Advanced Dupuytren's Disease · Australia3CompletedSep 200866
NCT00528931Dupuytren Contracture · United States1CompletedDec 200716
NCT00528840Advanced Dupuytren's Disease · United States3CompletedOct 2008201
NCT00528606Dupuytren Contracture · United States3CompletedApr 2008308
NCT00528424Advanced Dupuytren's Disease · United States3CompletedNov 2008286

How it is read

Names in the registry

  • “EN3835”, 9 entries
  • “Santyl”, 7 entries
  • “AA4500”, 7 entries
  • “collagenase clostridium histolyticum”, 5 entries
  • “Collagenase Clostridium Histolyticum”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.